Hybrid oligonucleotides: synthesis, biophysical properties, stability studies, and biological activity. 1996

D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
Hybridon Inc., Worcester, MA 01605, USA.

We have designed and synthesized hybrid oligonucleotides 2-5, as analogues of oligodeoxynucleoside phosphorothioates, in an effort to have agents with improved 'antisense activity' with reduced phosphorothioate content. The hybrid oligonucleotides contain segments of 2'-O-methyl ribonucleoside phosphoric diesters and oligodeoxynucleoside phosphorothioates. Thus, compared with the 'all' phosphorothioate analogues 1 and 6, the analogues 2-5 showed significantly reduced effect on complement activation. In addition, thermal denaturation studies with complementary RNA revealed that the analogues 2-5 had higher Tm compared with that with oligodeoxynucleoside phosphorothioates. Additionally, the RNA component of the oligo/ RNA duplex is efficiently cleaved by RNase H, the site of endonucleolytic cleavage being dictated by the length of the oligodeoxynucleoside phosphorothioate segment.

UI MeSH Term Description Entries
D009691 Nucleic Acid Denaturation Disruption of the secondary structure of nucleic acids by heat, extreme pH or chemical treatment. Double strand DNA is "melted" by dissociation of the non-covalent hydrogen bonds and hydrophobic interactions. Denatured DNA appears to be a single-stranded flexible structure. The effects of denaturation on RNA are similar though less pronounced and largely reversible. DNA Denaturation,DNA Melting,RNA Denaturation,Acid Denaturation, Nucleic,Denaturation, DNA,Denaturation, Nucleic Acid,Denaturation, RNA,Nucleic Acid Denaturations
D009841 Oligonucleotides Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed) Oligonucleotide
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D015941 Complement Hemolytic Activity Assay A screening assay for circulating COMPLEMENT PROTEINS. Diluted SERUM samples are added to antibody-coated ERYTHROCYTES and the percentage of cell lysis is measured. The values are expressed by the so called CH50, in HEMOLYTIC COMPLEMENT units per milliliter, which is the dilution of serum required to lyse 50 percent of the erythrocytes in the assay. CH50 Assay,Complement H50,Hemolytic Titration Assay,Serum Complement Titer,Total Hemolytic Complement,Whole Complement Titer,CH(50),Assay, CH50,Assay, Hemolytic Titration,Assays, CH50,Assays, Hemolytic Titration,CH50 Assays,Complement H50s,Complement, Total Hemolytic,Complements, Total Hemolytic,Hemolytic Complement, Total,Hemolytic Complements, Total,Hemolytic Titration Assays,Serum Complement Titers,Titer, Serum Complement,Titer, Whole Complement,Titers, Serum Complement,Titers, Whole Complement,Titration Assay, Hemolytic,Titration Assays, Hemolytic,Total Hemolytic Complements,Whole Complement Titers
D016914 Ribonuclease H A ribonuclease that specifically cleaves the RNA moiety of RNA:DNA hybrids. It has been isolated from a wide variety of prokaryotic and eukaryotic organisms as well as RETROVIRUSES. Endoribonuclease H,RNase H,Ribonuclease H, Calf Thymus,RNAase H
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
December 2014, Nucleic acids research,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
June 2023, Pharmaceutics,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
April 2017, Bioorganic & medicinal chemistry,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
September 1995, Nucleic acids research,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
January 2001, Nucleosides, nucleotides & nucleic acids,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
January 2007, Bioconjugate chemistry,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
February 1996, Anti-cancer drugs,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
October 2016, The Journal of organic chemistry,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
May 2023, Chembiochem : a European journal of chemical biology,
D Yu, and R P Iyer, and D R Shaw, and J Lisziewicz, and Y Li, and Z Jiang, and A Roskey, and S Agrawal
January 2000, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!